A panel of outside medical experts on Thursday is scheduled to discuss Merck & Co.'s third application to market cholesterol-lowering statin Mevacor without a prescription. The company is set to present before the FDA panel a new study that found stronger warnings on Mevacor helped consumers decide if the over-the-counter drug would benefit them.

Full Story:
USA Today

Related Summaries